Clinical Trial

A Study to Investigate GSK5733584 as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see how well GSK5733584 in combination with standard treatment of choice works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared to current standard of care. The study will also assess whether drug combination is safe and tolerated well by participants compared to the usual care and will help us better understand its impact on Health-Related Quality of Life of participants.
Trial Details
NCT Number NCT07684599
Lead Sponsor GlaxoSmithKline
Collaborators: ENGOT, GOG, APGOT
Conditions Neoplasms, Endometrial
Enrollment 610 participants
Start Date 2026-09-03
Primary Completion 2029-07-23 (estimated)
Study Completion 2031-09-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-15